HDAC (Histone Deacetylase) Inhibitors Market to Grow by USD 172.61 Mn, Curis Inc. and Bristol Myers Squibb Co. Among Key Vendors - Technavio

NEW YORK, Feb. 13, 2023 /PRNewswire/ -- The HDAC (histone deacetylase) Inhibitors Market by Route of Administration, Distribution Channel, and Geography - Forecast and Analysis 2023-2027 report has been published by Technavio. Market growth is estimated to accelerate at a CAGR of 7.73% and register an incremental growth of USD 172.61 million during the forecast period. The report includes historic market data from 2017 to 2021. In 2017, the HDAC (histone deacetylase) inhibitors market was valued at USD 302.55 million. The report provides a comprehensive analysis of growth opportunities at regional levels, new product launches, the latest trends, and the post-pandemic recovery of the global market. Download a PDF sample report

Company profiles

The HDAC (histone deacetylase) inhibitors market report includes information on the key products and recent developments of leading vendors, including:

• Acrotech Biopharma Inc.: The company offers beleodaq histone deacetylase inhibitor which is used to treat patients with peripheral T cell lymphoma.
• AstraZeneca Plc: The company offers histone deacetylase inhibitor AZD 9468 which is being designed to treat cancer as well as arthritis, multiple sclerosis and other noncancer medical conditions.
• Bristol Myers Squibb Co.: The company offers istodax histone deacetylase inhibitor which is used for the treatment of cutaneous T cell lymphoma in adult patients.
• Celleron Therapeutics Ltd.: The company offers zabinostat histone deacetylase inhibitor which is designed for the treatment of cancer.
• Syndax Pharmaceuticals Inc.
• Tokyo Chemical Industry Co. Ltd.
• Viracta Therapeutics Inc.
• Xynomic Pharmaceuticals (Nanjing) Co. Ltd.
• Cetya Therapeutics Inc.
• To gain access to more vendor profiles available with Technavio, buy the report!

Regional analysis

Based on region, the global HDAC (histone deacetylase) inhibitors market is segmented into North America, Europe, Asia, and Rest Of World (ROW). North America is estimated to account for 32% of the growth of the global market during the forecast period. The high prevalence of cancer and the increasing need for innovative medications are the major factors driving the market growth in this region. It also estimated that in 2020, around 1,806,590 new cases of cancer were diagnosed in the US, and 606,520 people died due to the disease. Such a high prevalence of cancer requires enhanced treatment options, including HDAC inhibitors. Such factors will increase the market growth in this region during the forecast period.

Market dynamics

The growth of the market depends on serval factors including high target affinity and specificity, high prevalence of oncology indications, and development of novel drug delivery systems and combination therapies. However, the high costs associated with treatment are hindering the market growth.

Competitive analysis

The report includes competitive analysis, a proprietary tool to analyze and evaluate the position of companies based on their industry position score and market performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc. Request a sample

Market segmentation

• Based on the route of administration, the market is segmented into (oral HDAC inhibitors and parenteral HDAC inhibitors). The oral HDAC inhibitors segment accounted for the largest share of the market in 2022.
• Based on geography, the market is segmented into North America, Europe, Asia, and Rest Of World (ROW). North America held the largest share of the market in 2022.

Related Reports:

The PD-1 and PD-L1 inhibitors market is estimated to grow at a CAGR of 19.31% between 2021 and 2026. The size of the market is forecasted to increase by USD 49.34 billion. This report extensively covers market segmentation by application (solid tumors and blood-related tumors) and geography (North America, Europe, Asia, and Rest of World (ROW)).

The tyrosine kinase inhibitors market size is expected to increase by USD 19.07 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 7.73%. This report extensively covers market segmentation by product (RTKIs and nRTKIs) and geography (North America, Europe, Asia, and the Rest of the World (ROW)).

Technavio's library includes over 17,000+ reports, covering more than 2,000 emerging technologies. Subscribe to our "Basic Plan" at just USD 5,000 and get lifetime access to Technavio Insights

What are the key data covered in this HDAC (histone deacetylase) inhibitors market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the HDAC (histone deacetylase) inhibitors market between 2023 and 2027
• Precise estimation of the HDAC (histone deacetylase) inhibitors market size and its contribution to the market in focus on the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the industry across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of HDAC (histone deacetylase) inhibitors market vendors

Table of contents:

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2022

• 3.4 Market outlook: Forecast for 2022-2027 
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global HDAC (histone deacetylase) inhibitors market 2017 - 2021 
• Exhibit 18: Historic Market Size – Data Table on Global HDAC (histone deacetylase) inhibitors market 2017 - 2021 ($ million)

• 4.2 Route of administration Segment Analysis 2017 - 2021
• Exhibit 19: Historic Market Size – Route of administration Segment 2017 - 2021 ($ million)

• 4.3 Distribution Channel Segment Analysis 2017 - 2021
• Exhibit 20: Historic Market Size – Distribution Channel Segment 2017 - 2021 ($ million)

• 4.4 Geography Segment Analysis 2017 - 2021 
• Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

• 4.5 Country Segment Analysis 2017 - 2021 
• Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary 
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry 
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition 
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Route of Administration

• 6.1 Market segments 
• Exhibit 30: Chart on Route of Administration - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Route of Administration - Market share 2022-2027 (%)

• 6.2 Comparison by Route of Administration 
• Exhibit 32: Chart on Comparison by Route of Administration
• Exhibit 33: Data Table on Comparison by Route of Administration

• 6.3 Oral HDAC inhibitors - Market size and forecast 2022-2027
• Exhibit 34: Chart on Oral HDAC inhibitors - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Oral HDAC inhibitors - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Oral HDAC inhibitors - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Oral HDAC inhibitors - Year-over-year growth 2022-2027 (%)

• 6.4 Parenteral HDAC inhibitors - Market size and forecast 2022-2027 
• Exhibit 38: Chart on Parenteral HDAC inhibitors - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Parenteral HDAC inhibitors - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Parenteral HDAC inhibitors - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Parenteral HDAC inhibitors - Year-over-year growth 2022-2027 (%)

• 6.5 Market opportunity by Route of Administration
• Exhibit 42: Market opportunity by Route of Administration ($ million)

7 Market Segmentation by Distribution Channel

• 7.1 Market segments 
• Exhibit 43: Chart on Distribution Channel - Market share 2022-2027 (%)
• Exhibit 44: Data Table on Distribution Channel - Market share 2022-2027 (%)

• 7.2 Comparison by Distribution Channel 
• Exhibit 45: Chart on Comparison by Distribution Channel
• Exhibit 46: Data Table on Comparison by Distribution Channel

• 7.3 Hospital pharmacies - Market size and forecast 2022-2027
• Exhibit 47: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 48: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 49: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
• Exhibit 50: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%)

• 7.4 Retail pharmacies - Market size and forecast 2022-2027
• Exhibit 51: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 52: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 53: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
• Exhibit 54: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)

• 7.5 Online pharmacies - Market size and forecast 2022-2027
• Exhibit 55: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 56: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 57: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%)
• Exhibit 58: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%)

• 7.6 Others - Market size and forecast 2022-2027
• Exhibit 59: Chart on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 60: Data Table on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 61: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibit 62: Data Table on Others - Year-over-year growth 2022-2027 (%)

• 7.7 Market opportunity by Distribution Channel
• Exhibit 63: Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 65: Chart on Market share by geography 2022-2027 (%)
• Exhibit 66: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 67: Chart on Geographic comparison
• Exhibit 68: Data Table on Geographic comparison

• 9.3 North America - Market size and forecast 2022-2027
• Exhibit 69: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 70: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 71: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 72: Data Table on North America - Year-over-year growth 2022-2027 (%)

• 9.4 Europe - Market size and forecast 2022-2027
• Exhibit 73: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 74: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 75: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 76: Data Table on Europe - Year-over-year growth 2022-2027 (%)

• 9.5 Asia - Market size and forecast 2022-2027
• Exhibit 77: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 78: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 79: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 80: Data Table on Asia - Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
• Exhibit 81: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 82: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 83: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 84: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

• 9.7 US - Market size and forecast 2022-2027
• Exhibit 85: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 86: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 87: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 88: Data Table on US - Year-over-year growth 2022-2027 (%)

• 9.8 Canada - Market size and forecast 2022-2027
• Exhibit 89: Chart on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 90: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 91: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibit 92: Data Table on Canada - Year-over-year growth 2022-2027 (%)

• 9.9 UK - Market size and forecast 2022-2027
• Exhibit 93: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%)

• 9.10 Germany - Market size and forecast 2022-2027
• Exhibit 97: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 98: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 99: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 100: Data Table on Germany - Year-over-year growth 2022-2027 (%)

• 9.11 China - Market size and forecast 2022-2027
• Exhibit 101: Chart on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 102: Data Table on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 103: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 104: Data Table on China - Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography 
• Exhibit 105: Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers

• 10.2 Market challenges

• 10.3 Impact of drivers and challenges 
• Exhibit 106: Impact of drivers and challenges in 2022 and 2027

• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview

• 11.2 Vendor landscape 
• Exhibit 107: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption 
• Exhibit 108: Overview on factors of disruption

• 11.4 Industry risks 
• Exhibit 109: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered 
• Exhibit 110: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 111: Matrix on vendor position and classification

• 12.3 Acrotech Biopharma Inc. 
• Exhibit 112: Acrotech Biopharma Inc. - Overview
• Exhibit 113: Acrotech Biopharma Inc. - Product / Service
• Exhibit 114: Acrotech Biopharma Inc. - Key offerings

• 12.4 AstraZeneca Plc 
• Exhibit 115: AstraZeneca Plc - Overview
• Exhibit 116: AstraZeneca Plc - Product / Service
• Exhibit 117: AstraZeneca Plc - Key news
• Exhibit 118: AstraZeneca Plc - Key offerings

• 12.5 Bristol Myers Squibb Co. 
• Exhibit 119: Bristol Myers Squibb Co. - Overview
• Exhibit 120: Bristol Myers Squibb Co. - Product / Service
• Exhibit 121: Bristol Myers Squibb Co. - Key news
• Exhibit 122: Bristol Myers Squibb Co. - Key offerings

• 12.6 Celleron Therapeutics Ltd. 
• Exhibit 123: Celleron Therapeutics Ltd. - Overview
• Exhibit 124: Celleron Therapeutics Ltd. - Key offerings

• 12.7 Curis Inc. 
• Exhibit 125: Curis Inc. - Overview
• Exhibit 126: Curis Inc. - Product / Service
• Exhibit 127: Curis Inc. - Key offerings

• 12.8 Huya Bioscience International LLC 
• Exhibit 128: Huya Bioscience International LLC - Overview
• Exhibit 129: Huya Bioscience International LLC - Product / Service
• Exhibit 130: Huya Bioscience International LLC - Key offerings

• 12.9 Italfarmaco Spa 
• Exhibit 131: Italfarmaco Spa - Overview
• Exhibit 132: Italfarmaco Spa - Product / Service
• Exhibit 133: Italfarmaco Spa - Key offerings

• 12.10 Medivir AB 
• Exhibit 134: Medivir AB - Overview
• Exhibit 135: Medivir AB - Product / Service
• Exhibit 136: Medivir AB - Key offerings

• 12.11 Merck and Co. Inc. 
• Exhibit 137: Merck and Co. Inc. - Overview
• Exhibit 138: Merck and Co. Inc. - Business segments
• Exhibit 139: Merck and Co. Inc. - Key news
• Exhibit 140: Merck and Co. Inc. - Key offerings
• Exhibit 141: Merck and Co. Inc. - Segment focus

• 12.12 Novartis AG 
• Exhibit 142: Novartis AG - Overview
• Exhibit 143: Novartis AG - Business segments
• Exhibit 144: Novartis AG - Key offerings
• Exhibit 145: Novartis AG - Segment focus

• 12.13 Onxeo SA 
• Exhibit 146: Onxeo SA - Overview
• Exhibit 147: Onxeo SA - Product / Service
• Exhibit 148: Onxeo SA - Key offerings

• 12.14 Shenzhen Chipscreen Biotechnology Co. Ltd.
• Exhibit 149: Shenzhen Chipscreen Biotechnology Co. Ltd. - Overview
• Exhibit 150: Shenzhen Chipscreen Biotechnology Co. Ltd. - Product / Service
• Exhibit 151: Shenzhen Chipscreen Biotechnology Co. Ltd. - Key offerings

• 12.15 Syndax Pharmaceuticals Inc. 
• Exhibit 152: Syndax Pharmaceuticals Inc. - Overview
• Exhibit 153: Syndax Pharmaceuticals Inc. - Key offerings

• 12.16 Viracta Therapeutics Inc. 
• Exhibit 154: Viracta Therapeutics Inc. - Overview
• Exhibit 155: Viracta Therapeutics Inc. - Product / Service
• Exhibit 156: Viracta Therapeutics Inc. - Key offerings

• 12.17 Xynomic Pharmaceuticals (Nanjing) Co. Ltd.
• Exhibit 157: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. - Overview
• Exhibit 158: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. - Product / Service
• Exhibit 159: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. - Key offerings

13 Appendix

• 13.1 Scope of the report

• 13.2 Inclusions and exclusions checklist 
• Exhibit 160: Inclusions checklist
• Exhibit 161: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 162: Currency conversion rates for US$

• 13.4 Research methodology 
• Exhibit 163: Research methodology
• Exhibit 164: Validation techniques employed for market sizing
• Exhibit 165: Information sources

• 13.5 List of abbreviations 
• Exhibit 166: List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio